Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Pharmaceutical Trade	3.05B
Pharmaceutical Trade Growth	23.23%
Pharmaceutical Manufacturing	2.17B
Pharmaceutical Manufacturing Growth	22.91%
Other Business	6.24M
Other Business Growth	-35.64%
Inter-segment Elimination	-2.09B
Inter-segment Elimination Growth	23.37%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	3.07B
China Growth	27.13%
Overseas	64.39M
Overseas Growth	-50.48%